THD Internal Medicine Grand Rounds - Racing toward a Cure for Blood Cancers in New CARs (CAR T-Cell Therapy)
Target Audience
This online educational enduring material is designed for physicians and clinical staff. Its purpose is to provide for the continuous educational need of the physicians to become more knowledgeable about the diseases in internal medicine subspecialties and become more efficient in the evaluation and management of concerns unique to their patients.
Learning Objectives
At the end of this online enduring material, participants should be able to:
- Discuss current FDA indications for CAR-T-Cell therapy in ALL and NHL (anti-CD19 CAR T-Cells)
- Identify the toxicities and limitations of CAR T-Cell therapy
- Review emerging data regarding use of CAR T-Cells in Multiple Myeloma
Available Credit
- 0.75 AMA PRA Category 1 Credit™
In support of improving patient care, Texas Health Resources is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The Texas Health Resources designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. - 0.75 Attendance